The role of gut bacteria in lung disease
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
This study is looking at how the bacteria in your gut, especially a type called Bifidobacterium, might affect lung health and the progression of idiopathic pulmonary fibrosis (IPF), with the hope of finding new ways to treat this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10885076 on NIH RePORTER |
What this research studies
This research investigates how the gut microbiome, particularly certain bacteria like Bifidobacterium, influences lung immunity and the progression of idiopathic pulmonary fibrosis (IPF). By examining the interactions between gut bacteria and the immune response in the lungs, the study aims to uncover mechanisms that could lead to new treatments for IPF. Researchers will utilize advanced gene sequencing techniques to analyze the microbiome and its effects on lung health. The findings could provide insights into how gut health impacts lung conditions and may lead to microbiome-based therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing significant lung impairment.
Not a fit: Patients with other forms of lung disease or those without a diagnosis of pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve lung health and quality of life for patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promising results in understanding the gut-lung axis, indicating that this approach may yield valuable insights into pulmonary diseases.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: O'dwyer, David Noel — University of Michigan at Ann Arbor
- Study coordinator: O'dwyer, David Noel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.